|
G |
Comt |
catechol-O-methyltransferase |
increases methylation |
ISO |
COMT protein results in increased methylation of 3,4-dihydroxyphenylglycol |
CTD |
PMID:11160877 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Mgll |
monoglyceride lipase |
affects response to substance |
ISO |
MGLL protein affects the susceptibility to 3,4-dihydroxyphenylglycol |
CTD |
PMID:21911610 |
|
NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
G |
Plcb1 |
phospholipase C beta 1 |
multiple interactions increases activity |
EXP |
[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein; Caffeine inhibits the reaction [3,4-dihydroxyphenylglycol results in increased activity of PLCB1 protein]; Caffeine inhibits the reaction [[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein]; Theophylline inhibits the reaction [3,4-dihydroxyphenylglycol results in increased activity of PLCB1 protein]; Theophylline inhibits the reaction [[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein] |
CTD |
PMID:15998294 |
|
NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of AKT1 mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:32344236 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of ATP2A2 protein]; astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of ATP2A2 mRNA] |
CTD |
PMID:17509559 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein] |
CTD |
PMID:22278385 PMID:33285147 PMID:36322813 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein] |
CTD |
PMID:33285147 PMID:36322813 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcs1l |
BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCS1L protein] |
CTD |
PMID:22278385 |
|
NCBI chr 9:76,164,925...76,168,940
Ensembl chr 9:76,164,932...76,168,938
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein] |
CTD |
PMID:33285147 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CASP3 protein modified form] astragaloside A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] |
CTD |
PMID:22278385 PMID:30842369 PMID:33285147 PMID:36322813 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein] |
CTD |
PMID:33285147 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
decreases expression multiple interactions |
ISO |
astragaloside IV decreases expression Dusp5 mRNA and protein in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate increases expression of DUSP5 mRNA and protein in Vascular smooth muscle cells] |
RGD |
PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of EGFR mRNA |
CTD |
PMID:32344236 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein] |
CTD |
PMID:33285147 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Gja4 |
gap junction protein, alpha 4 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of GJA4 protein] |
CTD |
PMID:36322813 |
|
NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [bisphenol A results in decreased activity of GLUL protein] |
CTD |
PMID:34434659 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of GPT protein] |
CTD |
PMID:30842369 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [bisphenol A affects the expression of GRIN2A mRNA] |
CTD |
PMID:34434659 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [bisphenol A affects the expression of GRIN2B mRNA] |
CTD |
PMID:34434659 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
H19 |
H19 imprinted maternally expressed transcript |
increases expression multiple interactions |
ISO |
astragaloside IV increases expression H19 RNA in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases expression of H19 RNA in Vascular smooth muscle cells] |
RGD |
PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134
|
|
G |
Hdac9 |
histone deacetylase 9 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of HDAC9 protein] |
CTD |
PMID:36322813 |
|
NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein astragaloside A results in increased expression of HMOX1 mRNA; astragaloside A results in increased expression of HMOX1 protein |
CTD |
PMID:25422538 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL1B protein; astragaloside A inhibits the reaction [Cisplatin results in increased expression of IL1B protein]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein] |
CTD |
PMID:25604657 PMID:30842369 PMID:32344236 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL6 protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein] astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein] |
CTD |
PMID:25604657 PMID:32344236 PMID:33285147 PMID:36322813 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Khdrbs1 |
KH RNA binding domain containing, signal transduction associated 1 |
decreases expression multiple interactions |
ISO |
astragaloside IV decreases expression of Khdrbs1 protein in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate astragaloside IV increases expression of KHDRBS1 protein in Vascular smooth muscle cells] |
RGD |
PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 5:142,051,844...142,089,175
Ensembl chr 5:142,063,570...142,089,180
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:33285147 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:33285147 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of MMP9 protein |
CTD |
PMID:32344236 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein] |
CTD |
PMID:25604657 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions increases phosphorylation |
EXP ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of MTOR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MTOR mRNA astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases phoshorylation of MTOR protein in Vascular smooth muscle cells] astragaloside IV increases phosphorylation Mtor protein in thoracic aorta |
CTD RGD |
PMID:32344236 PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5AC mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of MUC5AC protein |
CTD |
PMID:32344236 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Muc5b |
mucin 5B, oligomeric mucus/gel-forming |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5B mRNA |
CTD |
PMID:32344236 |
|
NCBI chr 1:196,916,861...196,948,830
Ensembl chr 1:196,916,825...196,949,250
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization |
ISO |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein astragaloside A affects the localization of NFE2L2 protein |
CTD |
PMID:25422538 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP ISO |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:25604657 PMID:33285147 PMID:36322813 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein] |
CTD |
PMID:25604657 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein] |
CTD |
PMID:30842369 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Pln |
phospholamban |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Isoproterenol results in decreased phosphorylation of PLN protein] |
CTD |
PMID:17509559 |
|
NCBI chr20:32,629,537...32,639,559
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein] |
CTD |
PMID:25604657 PMID:33285147 PMID:36322813 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rho |
rhodopsin |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA] |
CTD |
PMID:33285147 |
|
NCBI chr 4:148,975,597...148,988,693
Ensembl chr 4:148,980,611...148,985,773
|
|
G |
Rpe65 |
retinoid isomerohydrolase RPE65 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA] |
CTD |
PMID:33285147 |
|
NCBI chr 2:248,766,497...248,798,403
Ensembl chr 2:248,766,612...248,798,403
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein] |
CTD |
PMID:33285147 |
|
NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein] |
CTD |
PMID:25604657 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA] |
CTD |
PMID:25604657 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein] |
CTD |
PMID:30842369 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein] |
CTD |
PMID:33285147 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of TIMP1 protein |
CTD |
PMID:32344236 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of TNF protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein] astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein] |
CTD |
PMID:25604657 PMID:32344236 PMID:33285147 PMID:36322813 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport multiple interactions |
ISO |
ABCB1 protein results in increased transport of benzoylaconine [Cyclosporine results in decreased activity of ABCB1 protein] which results in decreased transport of benzoylaconine; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased transport of benzoylaconine |
CTD |
PMID:23200901 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[verlukast results in decreased activity of ABCC2 protein] which results in decreased transport of benzoylaconine |
CTD |
PMID:23200901 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport multiple interactions |
ISO |
ABCB1 protein results in increased transport of benzoylmesaconine [Cyclosporine results in decreased activity of ABCB1 protein] which results in decreased transport of benzoylmesaconine; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased transport of benzoylmesaconine |
CTD |
PMID:23200901 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[verlukast results in decreased activity of ABCC2 protein] which results in decreased transport of benzoylmesaconine |
CTD |
PMID:23200901 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
|
G |
Gba1 |
glucosylceramidase beta 1 |
multiple interactions decreases activity |
ISO EXP |
[conduritol epoxide binds to and results in decreased activity of GBA1 protein] which results in increased expression of SNCA protein [conduritol epoxide binds to and results in decreased activity of GBA1 protein] which affects the localization of SNCA protein; [conduritol epoxide binds to and results in decreased activity of GBA1 protein] which results in increased expression of SNCA protein conduritol epoxide analog results in decreased activity of GBA1 protein |
CTD |
PMID:9101438 PMID:19576930 |
|
NCBI chr 2:174,609,437...174,615,457
Ensembl chr 2:174,609,403...174,618,263
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
[conduritol epoxide binds to and results in decreased activity of GBA1 protein] which affects the localization of SNCA protein; [conduritol epoxide binds to and results in decreased activity of GBA1 protein] which results in increased expression of SNCA protein |
CTD |
PMID:19576930 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
|
G |
Arhgap17 |
Rho GTPase activating protein 17 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Arhgap17 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 1:177,807,579...177,897,027
Ensembl chr 1:177,807,583...177,896,854
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Bax protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Dsc2 |
desmocollin 2 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Dsc2 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr18:11,450,392...11,482,476
Ensembl chr18:11,450,390...11,482,392
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Gsk3b protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Ifng protein in spleen] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Ikbkg protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il10 protein in spleenocytes and peripheral blood] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il17 protein in spleenocytes and peripheral blood] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il1b protein in spleenocytes and peripheral blood] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Il4 protein in spleen] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il6 protein in spleenocytes and peripheral blood] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Mt-co2 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Plcg1 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Rhoa protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rit2 |
Ras-like without CAAX 2 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Rit2 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr18:22,565,403...22,921,648
Ensembl chr18:22,565,404...22,921,648
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Tnf protein in spleen] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Zeb1 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Dipyridamole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Dipyridamole results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
decreases activity multiple interactions |
ISO |
Dipyridamole results in decreased activity of ABCC4 protein Dipyridamole inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP] |
CTD |
PMID:11856762 PMID:15827327 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Adora3 |
adenosine A3 receptor |
increases expression |
EXP |
Dipyridamole results in increased expression of ADORA3 protein |
CTD |
PMID:17101059 |
|
NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with Atorvastatin co-treated with Valsartan] results in decreased expression of APOE protein |
CTD |
PMID:19603250 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 protein] |
CTD |
PMID:20063052 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp1 |
caspase 1 |
increases activity |
EXP |
Dipyridamole results in increased activity of CASP1 protein |
CTD |
PMID:21832250 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP3 protein]; Palmitic Acid promotes the reaction [Dipyridamole results in increased activity of CASP3 protein] |
CTD |
PMID:17303086 PMID:22700542 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity multiple interactions |
ISO |
Dipyridamole results in increased activity of CASP7 protein Palmitic Acid promotes the reaction [Dipyridamole results in increased activity of CASP7 protein] |
CTD |
PMID:22700542 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP8 protein] |
CTD |
PMID:17303086 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP ISO |
Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; tin protoporphyrin IX inhibits the reaction [Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]] Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein] |
CTD |
PMID:16765938 PMID:20940016 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd40lg |
CD40 ligand |
decreases secretion |
ISO |
Dipyridamole results in decreased secretion of CD40LG protein |
CTD |
PMID:16046616 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA alternative form]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR protein] |
CTD |
PMID:17303086 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cldn5 |
claudin 5 |
increases expression |
ISO |
Dipyridamole results in increased expression of CLDN5 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression |
ISO EXP |
Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]] Dipyridamole results in decreased expression of COL1A1 mRNA |
CTD |
PMID:7617123 PMID:11576339 PMID:12271277 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]] |
CTD |
PMID:11576339 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Dipyridamole results in decreased expression of CXCL12 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO mRNA]; Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO protein] |
CTD |
PMID:20063052 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Dipyridamole results in increased phosphorylation of DUSP1 protein DUSP1 mRNA affects the reaction [Dipyridamole inhibits the reaction [cobaltous chloride results in increased expression of SPP1 protein]]; HMOX1 mRNA affects the reaction [Dipyridamole results in increased phosphorylation of DUSP1 protein] DUSP1 mRNA affects the reaction [Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]] |
CTD |
PMID:16765938 PMID:19356721 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
decreases expression |
EXP |
Dipyridamole results in decreased expression of ENPP1 protein |
CTD |
PMID:21414308 |
|
NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715
|
|
G |
Fadd |
Fas associated via death domain |
increases expression multiple interactions |
ISO |
Dipyridamole results in increased expression of FADD mRNA Dipyridamole inhibits the reaction [Adenosine results in decreased expression of FADD mRNA] |
CTD |
PMID:17303086 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Dipyridamole results in increased expression of FOS mRNA |
CTD |
PMID:12730611 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP |
Dipyridamole results in increased expression of HMOX1 protein HMOX1 mRNA affects the reaction [Dipyridamole results in increased phosphorylation of DUSP1 protein] |
CTD |
PMID:19356721 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
Dipyridamole results in decreased expression of ICAM1 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased activity of IKBKB protein] |
CTD |
PMID:16765938 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Dipyridamole promotes the reaction [8-bromocyclic GMP promotes the reaction [IL1B protein results in increased abundance of Nitrites]]; Dipyridamole promotes the reaction [Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]]; Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; KT 5720 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; KT 5823 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:8904084 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
decreases expression |
ISO |
Dipyridamole results in decreased expression of IL2 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:16765938 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Insr |
insulin receptor |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [AICA ribonucleotide results in decreased activity of INSR promoter]; Dipyridamole inhibits the reaction [AICA ribonucleotide results in decreased expression of INSR mRNA]; Dipyridamole inhibits the reaction [AICA ribonucleotide results in decreased expression of INSR protein] |
CTD |
PMID:15694368 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Dipyridamole results in decreased activity of KCNH2 protein |
CTD |
PMID:17146843 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Lep |
leptin |
multiple interactions increases expression |
EXP |
1,3-dipropyl-8-cyclopentylxanthine inhibits the reaction [Dipyridamole results in increased expression of LEP protein] |
CTD |
PMID:10746648 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases activity |
ISO |
Dipyridamole results in increased activity of MAPK8 protein |
CTD |
PMID:11051267 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:16765938 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP ISO |
Dipyridamole results in increased expression of NOS2 mRNA; Dipyridamole results in increased expression of NOS2 protein Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:8904084 PMID:12271277 PMID:16765938 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
Dipyridamole results in increased expression of NPPB protein |
CTD |
PMID:18037770 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Orm1 |
orosomucoid 1 |
multiple interactions affects binding |
ISO |
Dipyridamole inhibits the reaction [Warfarin binds to ORM1 protein alternative form] Dipyridamole binds to ORM1 protein alternative form |
CTD |
PMID:8946472 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Pde10a |
phosphodiesterase 10A |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP] |
CTD |
PMID:10373451 |
|
NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
|
|
G |
Pde11a |
phosphodiesterase 11A |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP] |
CTD |
PMID:10725373 |
|
NCBI chr 3:60,913,562...61,297,154
Ensembl chr 3:60,913,562...61,297,158
|
|
G |
Pde4b |
phosphodiesterase 4B |
increases expression |
ISO |
Dipyridamole results in increased expression of PDE4B mRNA |
CTD |
PMID:20711499 |
|
NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pde5a |
phosphodiesterase 5A |
decreases activity |
ISO |
Dipyridamole results in decreased activity of PDE5A protein |
CTD |
PMID:11051267 |
|
NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Pde7a |
phosphodiesterase 7A |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10618442 |
|
NCBI chr 2:101,714,767...101,806,853
Ensembl chr 2:101,718,444...101,806,681
|
|
G |
Pde7b |
phosphodiesterase 7B |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10618442 PMID:10814504 PMID:10872825 |
|
NCBI chr 1:15,174,001...15,493,267
Ensembl chr 1:15,182,704...15,492,900
|
|
G |
Pde8a |
phosphodiesterase 8A |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP] Dipyridamole inhibits the reaction [PDE8A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:9671792 PMID:12681444 |
|
NCBI chr 1:135,166,143...135,288,986
Ensembl chr 1:135,166,237...135,288,024
|
|
G |
Pde8b |
phosphodiesterase 8B |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [PDE8B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP] |
CTD |
PMID:9784418 PMID:12681444 |
|
NCBI chr 2:26,275,117...26,479,725
Ensembl chr 2:26,276,635...26,509,209
|
|
G |
Plat |
plasminogen activator, tissue type |
increases secretion multiple interactions |
ISO |
Dipyridamole results in increased secretion of PLAT protein KT 5823 inhibits the reaction [Dipyridamole results in increased secretion of PLAT protein] |
CTD |
PMID:15733978 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO EXP |
Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; DUSP1 mRNA affects the reaction [Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; triptolide inhibits the reaction [Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]] Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; tin protoporphyrin IX inhibits the reaction [Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]] |
CTD |
PMID:16765938 PMID:20940016 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rcan1 |
regulator of calcineurin 1 |
affects binding |
ISO |
Dipyridamole binds to RCAN1 protein alternative form |
CTD |
PMID:19189965 |
|
NCBI chr11:31,622,208...31,702,150
Ensembl chr11:31,622,210...31,702,045
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [SLC22A2 protein polymorphism results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Dipyridamole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
multiple interactions decreases activity |
ISO |
Dipyridamole inhibits the reaction [4-nitrobenzylthioinosine binds to SLC29A1 protein]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Dipyridamole promotes the reaction [4-nitrobenzylthioinosine inhibits the reaction [[SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine]] Dipyridamole inhibits the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Dipyridamole promotes the reaction [[SLC29A1 co-treated with Oxygen deficiency] affects the abundance of Adenosine] Dipyridamole results in decreased activity of SLC29A1 protein |
CTD |
PMID:9353301 PMID:9396714 PMID:10366666 PMID:11085929 PMID:11179696 PMID:21678404 PMID:21872611 PMID:28041785 More...
|
|
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
|
|
G |
Slc29a2 |
solute carrier family 29 member 2 |
multiple interactions |
ISO |
Dipyridamole promotes the reaction [4-nitrobenzylthioinosine inhibits the reaction [[SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine]] Dipyridamole inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine] |
CTD |
PMID:10366666 PMID:11085929 |
|
NCBI chr 1:202,327,641...202,335,185
Ensembl chr 1:202,327,354...202,335,171
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [SLC47A1 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc4a1 |
solute carrier family 4 member 1 (Diego blood group) |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [SLC4A1 protein results in increased transport of Chlorides] |
CTD |
PMID:2511191 |
|
NCBI chr10:87,306,865...87,323,132
Ensembl chr10:87,306,872...87,323,117
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
Dinitrochlorobenzene inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; Dipyridamole inhibits the reaction [cobaltous chloride results in increased expression of SPP1 protein]; Dipyridamole inhibits the reaction [Glucose results in increased expression of SPP1 mRNA]; Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; DUSP1 mRNA affects the reaction [Dipyridamole inhibits the reaction [cobaltous chloride results in increased expression of SPP1 protein]]; KT 5823 inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; tin protoporphyrin IX inhibits the reaction [Dipyridamole inhibits the reaction [cobaltous chloride results in increased expression of SPP1 protein]] |
CTD |
PMID:19356721 PMID:20453393 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]] |
CTD |
PMID:11576339 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
decreases expression |
EXP |
Dipyridamole results in decreased expression of TH protein |
CTD |
PMID:17568153 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
Dipyridamole results in decreased expression of TNF mRNA |
CTD |
PMID:20711499 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
affects activity |
ISO |
Dipyridamole metabolite affects the activity of TP53 protein |
CTD |
PMID:35435491 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
EXP |
Dipyridamole inhibits the reaction [Glucose results in decreased expression of TXN1 protein]; KT 5823 inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in decreased expression of TXN1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in decreased expression of TXN1 protein]] |
CTD |
PMID:20453393 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
ISO |
Dipyridamole inhibits the reaction [UGT1A1 protein results in increased glucuronidation of anhydroicaritin] |
CTD |
PMID:30237061 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression |
ISO |
Dipyridamole results in decreased expression of VCAM1 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases secretion multiple interactions |
ISO |
Dipyridamole results in increased secretion of VEGFA protein Adenosine promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein]; Heparitin Sulfate promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein]; Hyaluronic Acid promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein]; Lipopolysaccharides promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein] |
CTD |
PMID:20067761 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity |
ISO |
madecassoside results in decreased activity of CYP2C19 protein |
CTD |
PMID:21349323 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
madecassoside results in decreased activity of CYP3A4 protein |
CTD |
PMID:21349323 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
Masoprocol binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
Masoprocol results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:19503098 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alk |
ALK receptor tyrosine kinase |
multiple interactions decreases activity |
ISO |
Masoprocol affects the phosphorylation of and affects the activity of ALK protein mutant form Masoprocol results in decreased activity of ALK protein |
CTD |
PMID:19503098 |
|
NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
multiple interactions decreases activity |
ISO EXP |
Masoprocol inhibits the reaction [ALOX12 protein results in increased chemical synthesis of 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid] Masoprocol results in decreased activity of ALOX12 protein |
CTD |
PMID:3928952 PMID:6240459 PMID:9258337 PMID:17027136 PMID:23238474 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions decreases activity |
EXP ISO |
Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] Masoprocol results in decreased activity of ALOX15 protein [Masoprocol results in decreased activity of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid |
CTD |
PMID:15574791 PMID:18984061 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
affects response to substance decreases activity multiple interactions |
ISO EXP |
ALOX5 protein affects the susceptibility to Masoprocol Masoprocol results in decreased activity of ALOX5 protein Masoprocol inhibits the reaction [[CCL5 protein co-treated with Calcimycin] results in increased expression of ALOX5 mRNA]; Masoprocol inhibits the reaction [[CCL5 protein co-treated with Calcimycin] results in increased expression of ALOX5 protein] [Masoprocol results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [Masoprocol results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; Masoprocol inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]] |
CTD |
PMID:2724698 PMID:2849922 PMID:3928952 PMID:6240459 PMID:10698703 PMID:18083043 PMID:19503098 More...
|
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ar |
androgen receptor |
affects binding |
EXP |
Masoprocol binds to AR protein |
CTD |
PMID:14565775 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Masoprocol results in increased expression of BAX protein MYC affects the reaction [Masoprocol results in increased expression of BAX protein] |
CTD |
PMID:15034932 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of BID protein |
CTD |
PMID:17645780 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases activity |
ISO EXP |
Masoprocol results in increased cleavage of CASP3 protein Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased cleavage of and results in increased activity of CASP3 protein]; Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased expression of CASP3 protein] acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Masoprocol results in increased activity of CASP3 protein]; Masoprocol inhibits the reaction [FASL protein results in increased activity of CASP3 protein] [Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:10203695 PMID:10653524 PMID:11470254 PMID:15034932 PMID:17645780 PMID:17651887 PMID:18645000 PMID:19503098 PMID:22308955 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases expression |
ISO |
[Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein Masoprocol inhibits the reaction [FASL protein results in increased activity of CASP8 protein] Masoprocol results in increased expression of CASP8 protein |
CTD |
PMID:10203695 PMID:17645780 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Masoprocol results in increased activity of CASP9 protein |
CTD |
PMID:15034932 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
Masoprocol inhibits the reaction [[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4]; Masoprocol inhibits the reaction [[CCL5 protein co-treated with Calcimycin] results in increased expression of ALOX5 mRNA]; Masoprocol inhibits the reaction [[CCL5 protein co-treated with Calcimycin] results in increased expression of ALOX5 protein] |
CTD |
PMID:18083043 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Masoprocol results in decreased expression of CCND1 protein |
CTD |
PMID:11953870 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh1 |
cadherin 1 |
decreases methylation increases expression |
ISO |
Masoprocol results in decreased methylation of CDH1 promoter Masoprocol results in increased expression of CDH1 mRNA; Masoprocol results in increased expression of CDH1 protein |
CTD |
PMID:18418215 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases methylation increases expression |
ISO |
Masoprocol results in decreased methylation of CDKN2A promoter Masoprocol results in increased expression of CDKN2A mRNA; Masoprocol results in increased expression of CDKN2A protein |
CTD |
PMID:18164318 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of CHUK protein modified form] |
CTD |
PMID:17395008 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
EXP |
Masoprocol promotes the reaction [sodium arsenite results in increased expression of CRYAB mRNA]; Masoprocol promotes the reaction [sodium arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:8591993 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
Masoprocol results in decreased activity of DIO1 protein |
CTD |
PMID:30561685 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
Masoprocol results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
Masoprocol results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [IGF1 protein results in increased phosphorylation of ERBB2 protein] |
CTD |
PMID:18645000 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Masoprocol binds to and results in increased activity of ESR1 protein |
CTD |
PMID:19063592 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
Masoprocol results in increased expression of FAS protein |
CTD |
PMID:17645780 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO EXP |
Masoprocol inhibits the reaction [FASL protein results in increased activity of CASP3 protein]; Masoprocol inhibits the reaction [FASL protein results in increased activity of CASP8 protein] Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased expression of FASLG protein] |
CTD |
PMID:10203695 PMID:17651887 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of and results in increased secretion of MMP13 protein]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of CHUK protein modified form]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of MAPK8 protein modified form]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of MAPK9 protein modified form]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of NFKBIA protein modified form]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of RELA protein modified form]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased phosphorylation of MAPK1 protein]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17395008 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of [FOS protein co-treated with JUN protein]] |
CTD |
PMID:10692565 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fpr1 |
formyl peptide receptor 1 |
decreases activity |
ISO |
Masoprocol results in decreased activity of FPR1 protein |
CTD |
PMID:17520823 |
|
NCBI chr 1:58,745,019...58,756,776
Ensembl chr 1:58,747,246...58,756,559
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP ISO |
Masoprocol results in increased expression of HMOX1 mRNA; Masoprocol results in increased expression of HMOX1 protein |
CTD |
PMID:18852027 PMID:23942037 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
multiple interactions increases expression increases activity |
ISO |
12-Hydroxy-5,8,10,14-eicosatetraenoic Acid inhibits the reaction [Masoprocol results in increased activity of HSD11B2 protein]; 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid inhibits the reaction [Masoprocol results in increased expression of HSD11B2 mRNA]; [Masoprocol co-treated with 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid] results in decreased expression of HSD11B2 protein; [Masoprocol co-treated with Leukotriene B4] results in decreased expression of HSD11B2 protein; Leukotriene B4 inhibits the reaction [Masoprocol results in increased activity of HSD11B2 protein]; Masoprocol inhibits the reaction [Progesterone results in decreased activity of HSD11B2 protein]; Masoprocol promotes the reaction [Mifepristone results in increased activity of HSD11B2 protein] |
CTD |
PMID:10377029 PMID:18032417 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [IGF1 protein promotes the reaction [IGF1R protein results in increased phosphorylation of and results in increased activity of IGF1R protein]]; Masoprocol inhibits the reaction [IGF1 protein results in increased phosphorylation of ERBB2 protein]; Masoprocol inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein] |
CTD |
PMID:18491370 PMID:18645000 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions decreases activity |
ISO |
Masoprocol inhibits the reaction [Dihydrotestosterone results in increased expression of IGF1R mRNA]; Masoprocol inhibits the reaction [Dihydrotestosterone results in increased expression of IGF1R protein]; Masoprocol inhibits the reaction [IGF1 protein promotes the reaction [IGF1R protein results in increased phosphorylation of and results in increased activity of IGF1R protein]]; Masoprocol inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein] Masoprocol results in decreased activity of IGF1R protein |
CTD |
PMID:18491370 PMID:18645000 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases response to substance |
ISO |
Masoprocol inhibits the reaction [Eicosapentaenoic Acid inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Masoprocol inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Masoprocol inhibits the reaction [IL1B protein results in increased expression of MMP13 protein] Masoprocol results in decreased susceptibility to IL1B protein Masoprocol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:8186192 PMID:12573452 PMID:21211511 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:8186192 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression multiple interactions |
ISO |
Masoprocol results in decreased expression of JUN mRNA Masoprocol inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of [FOS protein co-treated with JUN protein]] |
CTD |
PMID:10692565 PMID:15034932 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcna5 |
potassium voltage-gated channel subfamily A member 5 |
multiple interactions |
EXP |
Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] |
CTD |
PMID:18984061 |
|
NCBI chr 4:159,354,689...159,358,173
Ensembl chr 4:159,350,097...159,357,697
|
|
G |
Krt1 |
keratin 1 |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [Calcium results in increased expression of KRT1 mRNA] |
CTD |
PMID:12069687 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Masoprocol inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Pregnenolone]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Testosterone] |
CTD |
PMID:6430271 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
Masoprocol inhibits the reaction [FN1 protein modified form results in increased phosphorylation of MAPK1 protein] Masoprocol results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:17395008 PMID:19503098 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
ISO |
Masoprocol results in decreased phosphorylation of MAPK3 protein Masoprocol inhibits the reaction [FN1 protein modified form results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17395008 PMID:19503098 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of MAPK8 protein modified form] |
CTD |
PMID:17395008 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of MAPK9 protein modified form] |
CTD |
PMID:17395008 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of and results in increased secretion of MMP13 protein]; Masoprocol inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Masoprocol inhibits the reaction [IL1B protein results in increased expression of MMP13 protein]; Masoprocol inhibits the reaction [TNF protein results in increased expression of MMP13 mRNA]; Masoprocol inhibits the reaction [TNF protein results in increased expression of MMP13 protein] |
CTD |
PMID:17395008 PMID:21211511 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression multiple interactions |
ISO |
Masoprocol results in increased expression of MYC protein MYC affects the reaction [Masoprocol results in increased expression of BAX protein]; MYC affects the reaction [Masoprocol results in increased expression of MYC protein]; MYC affects the reaction [Masoprocol results in increased expression of TP53 protein] |
CTD |
PMID:15034932 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Masoprocol affects the localization of and results in increased activity of NFE2L2 protein |
CTD |
PMID:18852027 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of NFKBIA protein modified form] |
CTD |
PMID:17395008 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased expression of NGF mRNA]; Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased expression of NGF protein] |
CTD |
PMID:17651887 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
EXP |
Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased expression of NGFR mRNA]; Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased expression of NGFR protein] |
CTD |
PMID:17651887 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [Ritonavir results in decreased expression of NOS3 mRNA] |
CTD |
PMID:22037733 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein] |
CTD |
PMID:2105358 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Otc |
ornithine transcarbamylase |
multiple interactions |
EXP |
Masoprocol promotes the reaction [PRL protein results in increased activity of OTC protein] |
CTD |
PMID:3097147 |
|
NCBI chr X:12,453,834...12,529,954
Ensembl chr X:12,453,834...12,566,918
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Masoprocol affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of PCNA protein] |
CTD |
PMID:25770929 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [POR protein affects the reaction [Benzo(a)pyrene results in increased chemical synthesis of benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide-DNA]] |
CTD |
PMID:28111842 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Prl |
prolactin |
multiple interactions |
EXP |
Masoprocol promotes the reaction [PRL protein results in increased activity of OTC protein] |
CTD |
PMID:3097147 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [Eicosapentaenoic Acid inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Masoprocol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:7575673 PMID:12573452 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
Masoprocol results in decreased phosphorylation of RB1 protein |
CTD |
PMID:18164318 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of RELA protein modified form] |
CTD |
PMID:17395008 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
Masoprocol binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions |
EXP |
Masoprocol inhibits the reaction [TSHB protein results in increased expression of SLC5A5 mRNA] |
CTD |
PMID:17962351 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Masoprocol inhibits the reaction [TNF protein results in increased expression of SOD2 mRNA] |
CTD |
PMID:8760145 PMID:12031898 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation |
ISO |
Masoprocol results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:19503098 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
Masoprocol inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TGFB1 mRNA] |
CTD |
PMID:19194550 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases response to substance |
ISO |
Masoprocol inhibits the reaction [TNF protein results in increased expression of MMP13 mRNA]; Masoprocol inhibits the reaction [TNF protein results in increased expression of MMP13 protein]; Masoprocol inhibits the reaction [TNF protein results in increased expression of SOD2 mRNA] Masoprocol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] Masoprocol results in decreased susceptibility to TNF protein |
CTD |
PMID:8186192 PMID:8760145 PMID:21211511 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of BID protein; [Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP10 protein; [Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:17645780 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
MYC affects the reaction [Masoprocol results in increased expression of TP53 protein] |
CTD |
PMID:15034932 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
Masoprocol inhibits the reaction [[Melitten results in increased activity of TRPV1 protein] which results in increased transport of Calcium] |
CTD |
PMID:21453681 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
EXP |
Masoprocol inhibits the reaction [TSHB protein results in increased expression of SLC5A5 mRNA] |
CTD |
PMID:17962351 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of Masoprocol |
CTD |
PMID:14557274 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of Masoprocol |
CTD |
PMID:14557274 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Masoprocol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA mRNA]; Masoprocol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of VEGFA protein] |
CTD |
PMID:17520823 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation decreases expression |
EXP |
NDGA increases phosphorylation in liver of high fructose fed rats NDGA decreases expression of mRNA in liver of high fructose fed rats |
RGD |
PMID:26394137 PMID:26394137 |
RGD:329955565, RGD:329955565 |
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
decreases expression |
EXP |
NDGA decreases expression of Acacb protein in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
increases expression |
EXP |
NDGA increases expression of mRNA in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
EXP |
NDGA increases phosphorylation in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
EXP |
NDGA increases expression of mRNA in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
increases expression |
EXP |
NDGA increases expression of mRNA in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
decreases expression |
EXP |
NDGA decreases expression of mRNA in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
increases expression |
EXP |
NDGA increases expression of mRNA in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
EXP |
NDGA decreases expression of mRNA in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
decreases expression |
EXP |
NDGA decreases expression of mRNA in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
increases phosphorylation |
EXP |
NDGA increases phosphorylation in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation |
EXP |
NDGA increases phosphorylation in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Mlxipl |
MLX interacting protein-like |
decreases expression |
EXP |
NDGA decreases expression of mRNA in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mlycd |
malonyl-CoA decarboxylase |
increases expression |
EXP |
NDGA increases expression of Mlycd protein in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793
|
|
G |
Pklr |
pyruvate kinase L/R |
decreases expression |
EXP |
NDGA decreases expression of mRNA in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
EXP |
NDGA increases expression of Ppara protein in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
increases phosphorylation |
EXP |
NDGA increases phosphorylation in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
EXP |
NDGA decreases expression of mRNA, protein in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
EXP |
NDGA decreases expression of mRNA in liver of high fructose fed rats |
RGD |
PMID:26394137 |
RGD:329955565 |
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
purpurogallin inhibits the reaction [CYP2E1 protein results in increased reduction of tirapazamine] |
CTD |
PMID:7710944 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|